scholarly journals Change in pregnancy-associated multiple sclerosis relapse rates over time: a meta-analysis

2020 ◽  
Vol 44 ◽  
pp. 102241
Author(s):  
Ruth Dobson ◽  
Vilija G. Jokubaitis ◽  
Gavin Giovannoni
Keyword(s):  
Multiple Sclerosis ◽  
Meta Analysis ◽  
Multiple Sclerosis Relapse ◽  
Relapse Rates ◽  
Over Time ◽  
In Pregnancy

scholarly journals Explaining temporal trends in annualised relapse rates in placebo groups of randomised controlled trials in relapsing multiple sclerosis: systematic review and meta-regression

2013 ◽  
Vol 19 (12) ◽  
pp. 1580-1586 ◽  
Author(s):  
Simon M Steinvorth ◽  
Christian Röver ◽  
Simon Schneider ◽  
Richard Nicholas ◽  
Sebastian Straube ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Randomised Controlled Trials ◽  
Controlled Trials ◽  
Eligibility Criteria ◽  
Patient Age ◽  
Meta Regression ◽  
Randomised Controlled ◽  
Relapsing Multiple Sclerosis ◽  
Relapse Rates ◽  
Over Time

Background: Recent studies have shown a decrease in annualised relapse rates (ARRs) in placebo groups of randomised controlled trials (RCTs) in relapsing multiple sclerosis (RMS). Methods: We conducted a systematic literature search of RCTs in RMS. Data on eligibility criteria and baseline characteristics were extracted and tested for significant trends over time. A meta-regression was conducted to estimate their contribution to the decrease of trial ARRs over time. Results: We identified 56 studies. Patient age at baseline ( p < 0.001), mean duration of multiple sclerosis (MS) at baseline ( p = 0.048), size of treatment groups ( p = 0.003), Oxford Quality Scale scores ( p = 0.021), and the number of eligibility criteria ( p<0.001) increased significantly, whereas pre-trial ARR ( p = 0.001), the time span over which pre-trial ARR was calculated ( p < 0.001), and the duration of placebo-controlled follow-up ( p = 0.006) decreased significantly over time. In meta-regression of trial placebo ARR, the temporal trend was found to be insignificant, with major factors explaining the variation: pre-trial ARR, the number of years used to calculate pre-trial ARR and study duration. Conclusion: The observed decline in trial ARRs may result from decreasing pre-trial ARRs and a shorter time period over which pre-trial ARRs were calculated. Increasing patient age and duration of illness may also contribute.

scholarly journals Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients

CNS Drugs ◽  
2015 ◽  
Vol 29 (6) ◽  
pp. 503-510 ◽  
Author(s):  
Barbara H. Johnson ◽  
Machaon M. Bonafede ◽  
Crystal Watson
Keyword(s):  
Multiple Sclerosis ◽  
Propensity Score ◽  
Multiple Sclerosis Relapse ◽  
Time To Relapse ◽  
Relapse Rates

Multiple sclerosis relapse rates and healthcare costs of two versions of glatiramer acetate

2020 ◽  
Vol 36 (7) ◽  
pp. 1167-1175
Author(s):  
Benjamin Greenberg ◽  
Steven Hall ◽  
Michael Grabner ◽  
Sanjeev Balu ◽  
Xian Zhang ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Glatiramer Acetate ◽  
Healthcare Costs ◽  
Multiple Sclerosis Relapse ◽  
Relapse Rates

Oral and intravenous steroids for multiple sclerosis relapse: a systematic review and meta-analysis

2017 ◽  
Vol 264 (8) ◽  
pp. 1697-1704 ◽  
Author(s):  
Simona Lattanzi ◽  
Claudia Cagnetti ◽  
Maura Danni ◽  
Leandro Provinciali ◽  
Mauro Silvestrini
Keyword(s):  
Multiple Sclerosis ◽  
Systematic Review ◽  
Meta Analysis ◽  
Multiple Sclerosis Relapse ◽  
Intravenous Steroids

The effects of pregnancy on relapse rates, disability and peripartum outcomes in women with multiple sclerosis: a systematic review and meta-analysis

2021 ◽  
Vol 10 (3) ◽  
pp. 175-186
Author(s):  
Pedro J Modrego ◽  
Maria Añaños Urrea ◽  
Leyre Diaz de Cerio
Keyword(s):  
Multiple Sclerosis ◽  
Cohort Studies ◽  
Disease Activity ◽  
Relapse Rate ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Disability Progression ◽  
Obstetrical Outcomes ◽  
Lower Disease Activity ◽  
Relapse Rates

Background: Although previous cohort studies of women with multiple sclerosis (MS) yielded a reduction in relapse rate during pregnancy, the effect size has not been quantified in a comprehensive manner. In addition, the effects on disability progression and peripartum outcomes have been controversial. The purpose of this work is to assess the effect of pregnancy on disease activity, and to assess the effects of MS on pregnancy as well. Materials & methods: We searched in PubMed, Cochrane Library and EMBASE for cohort studies dealing with the effects of pregnancy on relapse rates, disability progression and peripartum outcomes in women with MS. The evaluated outcomes were: changes in the annualized relapse rate (ARR) in pregnancy and puerperium, disability worsening compared with the year before pregnancy, and peripartum outcomes, which were compared with the ones of non-MS women. In the majority of cohorts included here, the women were not under disease modifying therapies during pregnancy. Results: We found 23 cohort studies measuring changes in the ARR during pregnancy and puerperium; 12 were prospective and 11 retrospective. In 17 cohorts there was significant reduction in the ARR during pregnancy compared with prepregnancy period. The pooled mean reduction in the ARR was -0.5 (95% CI: 0.67–0.38), p < 0.001, from 15 cohorts included in meta-analysis. In 18 cohorts the ARR increased in the 3-month puerperium relative to prepregnancy year period; the pooled mean increase in the ARR was 0.22 (95% CI: 0.11–0.33), p < 0.001, from 14 cohorts included in meta-analysis. Disability worsening was addressed in 18 cohorts, and in 14 of them there were no significant changes. Peripartum complications and obstetrical outcomes were assessed in 16 cohorts, of whom 13 were retrospective, without finding significant differences. Conclusion: Pregnancy is associated with lower disease activity, and puerperium with higher disease activity. Disability does not change significantly after pregnancy. The obstetrical outcomes are not very different from those of non-MS women in most cohorts.

Factors that may contribute to multiple sclerosis relapse in Saudi Arabia

2020 ◽  
pp. 1721-1733
Author(s):  
Naif Alomairi ◽  
Sultan Bamusa ◽  
Mohammed Alzeer ◽  
Sultan Alamri
Keyword(s):  
Multiple Sclerosis ◽  
Saudi Arabia ◽  
Multiple Sclerosis Relapse
Sign in / Sign up

Export Citation Format

Share Document